Widget Image
Follow PPD Social Media
Follow Us:
Sunday, November 29, 2020
HomeNewsMarketsEquity Markets Surge Amid Positive Vaccine Report

Equity Markets Surge Amid Positive Vaccine Report

The New York Stock Exchange (NYSE) from the street level view of Wall Street Nassau Street during the Conoravirus (COVID-19) outbreak on March 18, 2020. (Photo: People's Pundit Daily)
The New York Stock Exchange (NYSE) from the street level view of Wall Street Nassau Street during the Conoravirus (COVID-19) outbreak on March 18, 2020. (Photo: People's Pundit Daily)
The New York Stock Exchange (NYSE) from the street level view of Wall Street Nassau Street during the Conoravirus (COVID-19) outbreak on March 18, 2020. (Photo: People’s Pundit Daily)

New York, N.Y. (PPD) — U.S. equity markets surged on Monday after interim data suggested strides are being made during vaccine trials for coronavirus (SARS-CoV-2), or COVID-19.

The Dow Jones Industrial Average (^DJI) gained +911.95, or 3.85% to close at 24,597.37. The S&P 500 (^SPX) gained +90.21, or 3.15% to close at 2,953.91. The NASDAQ Composite (^IXIC) gained +220.27, or 2.44% to close at 9,234.83.

The Russell 2000 (^RUT) was the biggest percentage gainer, closing up +76.70 or 6.10% at 1,333.69.

Moderna, Inc. (MRNA), which specializes in the development of transformative medicines based on messenger ribonucleic acid (mRNA), reported positive interim clinical data for its vaccine candidate. On May 7, the FDA completed its review of the Company’s IND application for mRNA-1273, allowing it to proceed to Phase 2.

Moderna is finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020. The Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 µg,” said Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna. “When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials.”

Moderna closed +13.31, or +19.96% at 80.00.

Written by
Staff Writing Group

PPD Business, the economy-reporting arm of People's Pundit Daily, is "making sense of current events." We are a no-holds barred, news reporting pundit of, by, and for the people.

No comments

leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

People's Pundit Daily
You have %%pigeonMeterAvailable%% free %%pigeonCopyPage%% remaining this month. Get unlimited access and support reader-funded, independent data journalism.

Start a 14-day free trial now. Pay later!

Start Trial